Etiopathogenesis of acquired cholesteatoma: Prominent theories and recent advances in biomolecular research

Laryngoscope

Volumn 125, Issue 1, 2015, Pages 234-240

  Kuo, Chin Lung ^a,b,c,d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

Author keywords

Connexin 26; Cytokines; Etiology; MicroRNA; Pathogenesis

Indexed keywords

ANGIOGENIC FACTOR; CYCLINE; CYTOKERATIN 13; CYTOKERATIN 16; KI 67 ANTIGEN; MICRORNA; THROMBOMODULIN; TRANSFORMING GROWTH FACTOR ALPHA; SIGNAL PEPTIDE;

ACQUIRED CHOLESTEATOMA; ANGIOGENESIS; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CHOLESTEATOMA; DNA DETERMINATION; EARDRUM PERFORATION; EPIGENETICS; GENE MUTATION; GENOMICS; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATION; OSTEOLYSIS; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL METAPLASIA; SYSTEMATIC REVIEW; AUDITORY TUBE; CELL MOTION; CHOLESTEATOMA, MIDDLE EAR; EPITHELIUM; GENETIC EPIGENESIS; GENETICS; GENOMIC INSTABILITY; HYPERPLASIA; LUNG VENTILATION; MASTOID; METAPLASIA; MIDDLE EAR; OTITIS MEDIA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

CELL MOVEMENT; CELL PROLIFERATION; CHOLESTEATOMA, MIDDLE EAR; EAR, MIDDLE; EPIGENESIS, GENETIC; EPITHELIUM; EUSTACHIAN TUBE; GENOMIC INSTABILITY; HUMANS; HYPERPLASIA; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MASTOID; METAPLASIA; OTITIS MEDIA; PULMONARY VENTILATION;

EID: 84919839383     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.24890     Document Type: Review

References (89)

1. Semaan MT, Megerian CA. The pathophysiology of cholesteatoma. Otolaryngol Clin North Am 2006;39:1143-1159
2. Sie KC. Cholesteatoma in children. Pediatr Clin North Am 1996;43:1245-1252
3. Wittmaack K. Wie entsteht ein genuines Cholesteatom? Arch Otorhinolaryngol 1933;137:306
4. Magnuson B. Tubal closing failure in retraction type cholesteatoma and adhesive middle ear lesions. Acta Otolaryngol 1978;86:408-417
5. Falk B, Magnuson B. Evacuation of the middle ear by sniffing: A cause of high negative pressure and development of middle ear disease. Otolaryngol Head Neck Surg 1984;92:312-318
6. Lindeman P, Holmquist J. Mastoid volume and eustachian tube function in ears with cholesteatoma. Am J Otol 1987;8:5-7
7. Sade J. Cellular differentiation of the middle ear lining. Ann Otol Rhinol Laryngol 1971;80:376-383
8. Sudhoff H, Tos M. Pathogenesis of attic cholesteatoma: Clinical and immunohistochemical support for combination of retraction theory and proliferation theory. Am J Otol 2000;21:786-792
9. Lau T, Tos M. Treatment of sinus cholesteatoma. Long-term results and recurrence rate. Arch Otolaryngol Head Neck Surg 1988;114:1428-1434
10. Habermann J. Zur Entsteheung des Cholesteatoms des Mittelohres. Archiv Hals Nasen Ohrenheilkunde 1888;27:43-51
11. Bezold F. Cholesteatom, Perforation derMembrana flaccida Shrapnelli und Tubenverschluss. Zeitschrift fuer Ohrenheilkunde 1890;20:5-29
12. Karmody CS, Northrop C. The pathogenesis of acquired cholesteatoma of the human middle ear: Support for the migration hypothesis. Otol Neurotol 2012;33:42-47
13. Jackson DG, Lim DJ. Fine morphology of the advancing front of cholesteatoma- experimental and human. Acta Otolaryngol 1978;86:71-88
14. Wendt H. Desquamative entundung des mittelohrs (Cholesteatom des Felsenbeins). Arch Heilkunde 1873;14:428
15. Gray JD. The chronic ear. The treatment of cholesteatoma in children. Proc R Soc Med 1964;57:769-771
16. Sadé J, Babiacki A, Pinkus G. The metaplastic and congenital origin of cholesteatoma. Acta Otolaryngol 1983;96:119-129
17. Yamamoto-Fukuda T, Hishikawa Y, Shibata Y, Kobayashi T, Takahashi H, Koji T. Pathogenesis of middle ear cholesteatoma: A new model of experimentally induced cholesteatoma in Mongolian gerbils. Am J Pathol 2010;176:2602-2606
18. Lange W. Über die Entstehung der Mittelohrcholesteatoma. Z Hals Nas Ohrenheilk 1925;11:250-271
19. Chole RA, Tinling SP. Basal lamina breaks in the histogenesis of cholesteatoma. Laryngoscope 1985;95:270-275
20. Yamamoto-Fukuda T, Takahashi H, Koji T. Animal models of middle ear cholesteatoma. J Biomed Biotechnol 2011;2011:394241
21. Olszewska E, Wagner M, Bernal-Sprekelsen M, et al. Etiopathogenesis of cholesteatoma. Eur Arch Otorhinolaryngol 2004;261:6-24
22. Bujia J, Holly A, Sudhoff H, Antoli-Candela F, Tapia MG, Kastenbauer E. Identification of proliferating keratinocytes in middle ear cholesteatoma using the monoclonal antibody Ki-67. ORL J Otorhinolaryngol Relat Spec 1996;58:23-26
23. Bujia J, Sudhoff H, Holly A, Hildmann H, Kastenbauer E. Immunohistochemical detection of proliferating cell nuclear antigen in middle ear cholesteatoma. Eur Arch Otorhinolaryngol 1996;253:21-24
24. Bassiouny M, Badour N, Omran A, Osama H. Histopathological and immunohistochemical characteristics of acquired cholesteatoma in children and adults. Egypt J Ear Nose Throat Allied Sci 2012;13:7-12
25. Albino AP, Kimmelman CP, Parisier SC. Cholesteatoma: A molecular and cellular puzzle. Am J Otol 1998;19:7-19
26. Macias JD, Gerkin RD, Locke D, Macias MP. Differential gene expression in cholesteatoma by DNA chip analysis. Laryngoscope 2013;123(suppl S5):S1-S21
27. Klenke C, Janowski S, Borck D, et al. Identification of novel cholesteatoma-related gene expression signatures using full-genome microarrays. PLoS One 2012;7:e52718
28. Jin BJ, Min HJ, Jeong JH, Park CW, Lee SH. Expression of EGFR and microvessel density in middle ear cholesteatoma. Clin Exp Otorhinolaryngol 2011;4:67-71
29. Reinartz JJ, George E, Lindgren BR, Niehans GA. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994;25:1075-1083
30. Khazaie K, Schirrmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 1993;12:255-274
31. Ergun S, Zheng X, Carlsoo B. Expression of transforming growth factoralpha and epidermal growth factor receptor in middle ear cholesteatoma. Am J Otol 1996;17:393-396
32. Shinoda H, Huang CC. Expressions of c-jun and p53 proteins in human middle ear cholesteatoma: relationship to keratinocyte proliferation, differentiation, and programmed cell death. Laryngoscope 1995;105:1232-1237
33. Holly A, Sittinger M, Bujia J. Immunohistochemical demonstration of c-myc oncogene product in middle ear cholesteatoma. Eur Arch Otorhinolaryngol 1995;252:366-369
34. Palko E, Poliska S, Csakanyi Z, et al. The c-MYC protooncogene expression in cholesteatoma. Biomed Res Int 2014;2014:639896
35. Ozturk K, Yildirim MS, Acar H, Cenik Z, Keles B. Evaluation of c-MYC status in primary acquired cholesteatoma by using fluorescence in situ hybridization technique. Otol Neurotol 2006;27:588-591
36. Ecsedi S, Rakosy Z, Vizkeleti L, et al. Chromosomal imbalances are associated with increased proliferation and might contribute to bone destruction in cholesteatoma. Otolaryngol Head Neck Surg 2008;139:635-640
37. Choung YH, Park K, Kang SO, Markov Raynov A, Ho Kim C, Choung PH. Expression of the gap junction proteins connexin 26 and connexin 43 in human middle ear cholesteatoma. Acta Otolaryngol 2006;126:138-143
38. James AL, Chadha NK, Papsin BC, Stockley TL. Pediatric cholesteatoma and variants in the gene encoding connexin 26. Laryngoscope 2010;120: 183-187
39. Maniu A, Harabagiu O, Perde Schrepler M, Catana A, Fanuta B, Mogoanta CA. Molecular biology of cholesteatoma. Rom J Morphol Embryol 2014;55:7-13
40. Bayazit YA, Karakok M, Ucak R, Kanlikama M. Cycline-dependent kinase inhibitor, p27 (KIP1), is associated with cholesteatoma. Laryngoscope 2001;111:1037-1041
41. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266: 1821-1828
42. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011;192:209-218
43. Hussein MR, Al-Badaiwy ZH, Guirguis MN. Analysis of p53 and bcl-2 protein expression in the non-tumorigenic, pretumorigenic, and tumorigenic keratinocytic hyperproliferative lesions. J Cutan Pathol 2004;31:643-651
44. Welkoborsky HJ, Jacob RS, Hinni ML. Comparative analysis of the epithelium stroma interaction of acquired middle ear cholesteatoma in children and adults. Eur Arch Otorhinolaryngol 2007;264:841-848
45. Mallet Y, Nouwen J, Lecomte-Houcke M, Desaulty A. Aggressiveness and quantification of epithelial proliferation of middle ear cholesteatoma by MIB1. Laryngoscope 2003;113:328-331
46. Caglar O, Bulbul F, Sennaroglu L. Incidence of otitis media with effusion and long-term clinical findings in children with cleft lip and palate types. Kulak Burun Bogaz Ihtis Derg 2013;23:268-274
47. Uchida N, Ito S, Hirano M. Localization of proliferating cell nuclear antigen in aural cholesteatoma. Kurume Med J 1993;40:225-228
48. Bollmann R, Knopp U, Tolsdorff P. DNA cytometric studies of cholesteatoma of the middle ear [in German]. HNO 1991;39:313-314
49. Desloge RB, Carew JF, Finstad CL, et al. DNA analysis of human cholesteatomas. Am J Otol 1997;18:155-159
50. Rudnicki A, Avraham KB. microRNAs: The art of silencing in the ear. EMBO Mol Med 2012;4:849-859
51. Chen X, Qin Z. Post-transcriptional regulation by microrna-21 and let-7a microRNA in paediatric cholesteatoma. J Int Med Res 2011;39:2110-2118
52. Hui AB, Lenarduzzi M, Krushel T, et al. Comprehensive microRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 2010; 16:1129-1139
53. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297
54. Friedland DR, Eernisse R, Erbe C, Gupta N, Cioffi JA. Cholesteatoma growth and proliferation: Posttranscriptional regulation by microRNA- 21. Otol Neurotol 2009;30:998-1005
55. Ambros V. A hierarchy of regulatory genes controls a larva-to-Adult developmental switch in C. elegans. Cell 1989;57:49-57
56. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001;294:862-864
57. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001;294:858-862
58. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001;294:853-858
59. Bujia J, Holly A, Antoli-Candela F, Tapia MG, Kastenbauer E. Immunobiological peculiarities of cholesteatoma in children: Quantification of epithelial proliferation by MIB1. Laryngoscope 1996;106:865-868
60. Fedele M, Battista S, Kenyon L, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002;21:3190-3198
61. Ferlito A, Devaney KO, Rinaldo A, et al. Clinicopathological consultation. Ear cholesteatoma versus cholesterol granuloma. Ann Otol Rhinol Laryngol 1997;106:79-85
62. Preciado DA. Biology of cholesteatoma: Special considerations in pediatric patients. Int J Pediatr Otorhinolaryngol 2012;76:319-321
63. Kojima H, Tanaka Y, Tanaka T, et al. Cell proliferation and apoptosis in human middle ear cholesteatoma. Arch Otolaryngol Head Neck Surg 1998;124:261-264
64. Yoshikawa M, Kojima H, Yaguchi Y, Okada N, Saito H, Moriyama H. Cholesteatoma fibroblasts promote epithelial cell proliferation through overexpression of epiregulin. PLoS One 2013;8:e66725
65. Raynov AM, Choung YH, Park HY, Choi SJ, Park K. Establishment and characterization of an in vitro model for cholesteatoma. Clin Exp Otorhinolaryngol 2008;1:86-91
66. Cheshire IM, Blight A, Ratcliffe WA, Proops DW, Heath DA. Production of parathyroid-hormone-related protein by cholesteatoma cells in culture. Lancet 1991;338:1041-1043
67. Yetiser S, Satar B, Aydin N. Expression of epidermal growth factor, tumor necrosis factor-Alpha, and interleukin-1alpha in chronic otitis media with or without cholesteatoma. Otol Neurotol 2002;23:647-652
68. Chung JW, Yoon TH. Different production of interleukin-1alpha, interleukin- 1beta and interleukin-8 from cholesteatomatous and normal epithelium. Acta Otolaryngol 1998;118:386-391
69. Schilling V, Negri B, Bujia J, Schulz P, Kastenbauer E. Possible role of interleukin 1 alpha and interleukin 1 beta in the pathogenesis of cholesteatoma of the middle ear. Am J Otol 1992;13:350-355
70. Lang S, Schilling V, Wollenberg B, Mack B, Nerlich A. Localization of transforming growth factor-beta-expressing cells and comparison with major extracellular components in aural cholesteatoma. Ann Otol Rhinol Laryngol 1997;106:669-673
71. Schulz P, Bujia J, Holly A, Shilling V, Kastenbauer E. Possible autocrine growth stimulation of cholesteatoma epithelium by transforming growth factor alpha. Am J Otolaryngol 1993;14:82-87
72. Sudhoff H, Dazert S, Gonzales AM, et al. Angiogenesis and angiogenic growth factors in middle ear cholesteatoma. Am J Otol 2000;21:793-798
73. Fukudome S, Wang C, Hamajima Y, et al. Regulation of the angiogenesis of acquired middle ear cholesteatomas by inhibitor of DNA binding transcription factor. JAMA Otolaryngol Head Neck Surg 2013;139:273-278
74. Walsh TE, Covell WP, Ogura JH. The effect of cholesteatosis on bone. Ann Otol Rhinol Laryngol 1951;60:1100-1113
75. Ahn JM, Huang CC, Abramson M. Third place-Resident Basic Science Award 1990. Interleukin 1 causing bone destruction in middle ear cholesteatoma. Otolaryngol Head Neck Surg 1990;103:527-536
76. Haruyama T, Furukawa M, Kusunoki T, Onoda J, Ikeda K. Expression of IL-17 and its role in bone destruction in human middle ear cholesteatoma. ORL J Otorhinolaryngol Relat Spec 2010;72:325-331
77. Kawai T, Matsuyama T, Hosokawa Y, et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 2006;169:987-998
78. Dornelles Cde C, da Costa SS, Meurer L, Rosito LP, da Silva AR, Alves SL. Comparison of acquired cholesteatoma between pediatric and adult patients. Eur Arch Otorhinolaryngol 2009;266:1553-1561
79. Kaya E, Dag I, Incesulu A, Gurbuz MK, Acar M, Birdane L. Investigation of the presence of biofilms in chronic suppurative otitis media, nonsuppurative otitis media, and chronic otitis media with cholesteatoma by scanning electron microscopy. ScientificWorldJournal 2013;2013:638715
80. Chole RA, Faddis BT. Evidence for microbial biofilms in cholesteatomas. Arch Otolaryngol Head Neck Surg 2002;128:1129-1133
81. Okumus S, Taysi S, Orkmez M, et al. The effects of oral Ginkgo biloba supplementation on radiation-induced oxidative injury in the lens of rat. Pharmacogn Mag 2011;7:141-145
82. Baysal E, Aksoy N, Kara F, et al. Oxidative stress in chronic otitis media. Eur Arch Otorhinolaryngol 2013;270:1203-1208
83. Garca MF, Aslan M, Tuna B, Kozan A, Cankaya H. Serum myeloperoxidase activity, total antioxidant capacity and nitric oxide levels in patients with chronic otitis media. J Membr Biol 2013;246:519-524
84. Kaneko Y, Yuasa R, Ise I, et al. Bone destruction due to the rupture of a cholesteatoma sac: A pathogenesis of bone destruction in aural-cholesteatoma. Laryngoscope 1980;90:1865-1871
85. Nguyen KH, Suzuki H, Ohbuchi T, et al. Possible participation of acidic pH in bone resorption in middle ear cholesteatoma. Laryngoscope 2014; 124:245-250
86. Iino Y, Hoshino E, Tomioka S, Takasaka T, Kaneko Y, Yuasa R. Organic acids and anaerobic microorganisms in the contents of the cholesteatoma sac. Ann Otol Rhinol Laryngol 1983;92:91-96
87. Rothschild S, Ciernik IF, Hartmann M, Schuknecht B, Lutolf UM, Huber AM. Cholesteatoma triggering squamous cell carcinoma: Case report and literature review of a rare tumor. Am J Otolaryngol 2009;30:256-260
88. Takahashi K, Yamamoto Y, Sato K, Sato Y, Takahashi S. Middle ear carcinoma originating from a primary acquired cholesteatoma: A case report. Otol Neurotol 2005;26:105-108
89. Westerman ST, Sylvia LC, Tepper E. Carcinoma arising out of a primary acquired cholesteatoma. J Med Soc N J 1981;78:600-602.